Third Harmonic Bio is a clinical-stage biopharmaceutical company developing a highly selective, oral KIT inhibitor for treatment of dermal, respiratory and gastrointestinal inflammatory diseases. KIT is a cell surface receptor that acts as the master survival and functional regulator of mast cells, which are immune cells concentrated at the body’s interfaces with the external environment and that act as the key mediator of the inflammation associated with mast-cell mediated inflammatory diseases. By inhibiting KIT, we believe we can provide broad symptomatic relief to patients with a range of disorders, including chronic spontaneous urticaria and severe asthma.
Company Details
- Employees
- 34
- Founded
- -
- Address
- 1700 Montgomery St, Suite 210,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://thirdharmonicbio.com/
- HQ
- San Francisco, California
Third Harmonic Bio Questions
Third Harmonic Bio's website is https://thirdharmonicbio.com/
Third Harmonic Bio's LinkedIn profile is https://www.linkedin.com/company/third-harmonic-bio
Third Harmonic Bio has
34 employees.
View email and phone details for 34
employees at Third Harmonic Bio.
Third Harmonic Bio's industry is
Biotechnology Research
Third Harmonic Bio's top competitors are
Neumora,
Aardvark Therapeutics,
Spruce Biosciences,
Tempest Therapeutics,
Kojin Therapeutics,
Anthos Therapeutics,
Mural Oncology,
Inventiva Pharma,
Caribou Biosciences,
Xilio Therapeutics, Inc..
Third Harmonic Bio's categories are Biotechnology Research
Third Harmonic Bio's founding year is 2019
